Study: New blood thinner works as well as Coumadin

Nov 15, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- A study finds that a new and easier-to-use blood thinner prevents strokes in people with a common heart rhythm problem as well as Coumadin does, and without an increase in bleeding or side effects.

The drug is called rivaroxaban (riv-ah-ROCKS-ah-ban). It was tested against warfarin, the generic version of Coumadin, in more than 14,000 people with atrial . That's the most common heart rhythm problem in America. It occurs when the upper parts of the heart quiver instead of beating normally. This raises the risk of clots that can cause a .

Johnson & Johnson and Bayer Healthcare plan to seek federal approval to sell the drug later this year. Doctors gave results of the study Monday at a heart conference in Chicago.

Explore further: FDA approves Biogen's MS drug Plegridy

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study: Plavix plus aspirin helps prevent strokes

Mar 31, 2009

(AP) -- Taking the blood thinner Plavix along with aspirin helped prevent strokes and heart attacks in people with a common heartbeat abnormality that puts them at high risk of these problems, doctors reported Tuesday.

Blood-Thinning Drug Linked to Increased Bleeding in Brain

Sep 29, 2008

(PhysOrg.com) -- Patients who take the commonly used blood-thinning drug warfarin face larger amounts of bleeding in the brain and increased risk of mortality if they suffer a hemorrhagic stroke, new research from the University ...

Blood thinner causes stroke in some dialysis patients

Aug 27, 2009

The blood thinner warfarin can prevent strokes in most individuals with abnormal heart rhythms, but the drug may have the opposite effect in kidney disease patients on dialysis, according to a study appearing in an upcoming ...

Recommended for you

Boxed warnings are common in novel therapeutics

16 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

17 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

18 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0